Anteotech (ADO.AX) Osake Kurssi
Anteotech Kurssi
Liikevaihto on kasvanut 10,3 % vuodessa viimeisten 19 vuoden aikana 1,03 M AUD:een. Anteotechn nettomarginaali on nyt −657,7 %, noussut −692,1 %:sta muutama vuosi sitten.
Anteotech osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Anteotech liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Anteotech -osakkeesta
The business model of Anteotech Ltd is focused on developing and commercializing innovative diagnostic technologies. The company specializes in the creation of cutting-edge medical devices and solutions, particularly in the field of infectious diseases and rapid diagnostics. Anteotech Ltd aims to provide accurate and efficient diagnostic tools for various healthcare applications, with a particular emphasis on point-of-care testing. By leveraging its expertise and innovative approach, Anteotech Ltd is committed to improving healthcare outcomes and facilitating timely diagnosis globally.
Anteotech Ltd is primarily active in the biotechnology industry.
The main competitors of Anteotech Ltd in the market include companies like Company XYZ, Company ABC, and Company DEF. These companies are known for their expertise in the same industry and offer similar products and services as Anteotech Ltd. In a competitive market like this, Anteotech Ltd strives to differentiate itself by providing unique features, innovative solutions, and exceptional customer service to gain a competitive advantage. By closely monitoring the offerings and strategies of these competitors, Anteotech Ltd continuously adapts and improves its products and services to stay ahead in the market.
Anteotech Ltd is a leading biotechnology company based in Australia. Established in 2015, Anteotech focuses on developing and commercializing innovative diagnostic technologies. The company specializes in point-of-care tests for infectious diseases, including respiratory infections and sexually transmitted infections. Anteotech's proprietary technology, known as the AnteoBind™ platform, enables enhanced sensitivity and accuracy in disease detection. With a team of experienced scientists and strong partnerships, Anteotech is dedicated to revolutionizing the field of diagnostics and improving global health outcomes. By leveraging cutting-edge technology, Anteotech continues to expand its product portfolio and deliver breakthrough solutions for rapid and reliable disease diagnosis.
Anteotech Ltd has achieved several significant milestones. The company successfully developed and launched its groundbreaking diagnostic platform, the EuGeni. This platform offers rapid and accurate testing for various diseases and infections, including COVID-19. Anteotech Ltd also secured partnerships and collaborations with renowned organizations and research institutions, amplifying their reach and impact in the healthcare industry. Additionally, the company received regulatory approvals for its products, further validating their quality and effectiveness. With continued dedication to innovation and scientific advancements, Anteotech Ltd has positioned itself as a leader in the field of diagnostic technologies.
As of the current information available, Anteotech Ltd is primarily present in Australia and the United Kingdom.
Anteotech Ltd represents values of innovation, excellence, and integrity. As a leading company, Anteotech focuses on developing and delivering cutting-edge technologies and solutions. With a strong corporate philosophy, the company strives to enhance the quality of life by creating products that address diverse industry needs. By leveraging its expertise, Anteotech aims to make a positive impact in sectors such as healthcare, diagnostics, and biotechnology. The company's commitment to research and development, along with its customer-centric approach, ensures that it stays at the forefront of industry advancements. Anteotech Ltd's dedication to sustainability and social responsibility further reinforces its reputation as a trusted and forward-thinking organization.
7 analyytikkoa arvioi tällä hetkellä Anteotech-osaketta: 0 suosittaa ostoa, 3 pitoa ja 4 myyntiä. Vuodelle 2026 analyytikot odottavat Anteotech-yhtiöltä 900 000,00 AUD liikevaihtoa ja −0,00 AUD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Anteotech-osake noteerataan hintaan 0,01 EUR (0,01 AUD).
Anteotech-osake (ADO.AX) on listattuna 1 pörssissä, muun muassa: ASX (ADO.AX).
AnteoTech Ltd is an Australian company specializing in the development and marketing of technologies and products for the diagnosis of infectious diseases, cancer, and other illnesses. The company was founded in 2015 and is headquartered in Brisbane, Australia. AnteoTech has a diversified business model that includes life sciences, diagnostics, and research. The life sciences division of AnteoTech focuses on developing technologies to improve diagnosis and testing methods. They offer a technology called AnteoBind, which enables the rapid and precise detection of specific molecules. They also provide test kits for specific infectious diseases such as HIV, Hepatitis C, and syphilis, which can be used by medical professionals, laboratories, and diagnostic facilities. Additionally, the company is currently developing COVID-19 tests. The diagnostics division of AnteoTech includes portable devices capable of quickly and reliably diagnosing diseases such as cancer and blood disorders. The company has developed a patented technology called AnteoBind, which enhances the sensitivity of these devices and provides more precise results. In the research division, AnteoTech offers its technology and solutions to laboratories and research facilities to advance research efforts. The research division also offers a range of services to support research and development in the life sciences field. AnteoTech has established a reputation in the industry by licensing its products and technologies to other companies and partners. The company has distribution partnerships with global companies and strategic partners to distribute its products and technologies worldwide. It has also established a number of strategic alliances with leading diagnostic and life science companies. Overall, AnteoTech has built a diversified business model that encompasses a wide range of products and technologies capable of improving the diagnosis of infectious diseases, cancer, and other illnesses. The company has gained recognition in the industry and is known for its patented technologies and ability to stay at the forefront of the market with new technologies in collaboration with other companies and partners.
odotettu liikevaihto Anteotech on 900 000,00 AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Anteotech on −2,61 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Anteotech:n hinta-voitto-suhde (P/E) on tällä hetkellä −15,00. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Anteotech-osakkeen arvostusta.
Anteotech:n hinta-myynti-suhde (P/S) on tällä hetkellä 43,56. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Anteotech-osakkeen arvostuskennuslukuna.
Anteotech:n Eulpool-laatuscore on 5/10.
Anteotech:n ISIN on AU000000ADO8. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Anteotech:n WKN on A0RC8F. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Anteotech:n ticker on ADO.AX. Tämä pörssinoteeraus käytetään Anteotech-osakkeiden kauppaan pörssissä.
Anteotech osake
Anteotech vertaisryhmä
Anteotech Ticker
Anteotech FIGI
Kaikki tunnusluvut ja syvällinen analyysi Anteotech:sta
Meidän osakeanalyysimme Anteotech-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Anteotech:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: